| Natural Antidiabetic Agents Studies | Lifetime | 73 | IN 5 | 98.96 |
| Diverse Scientific Research Studies | Lifetime | 22 | IN 9 | 96.03 |
| COVID-19 Clinical Research Studies | Lifetime | 947 | IN 21 | 96.93 |
| Medicinal Plants and Bioactive Compounds | Lifetime | 85 | IN 7 | 94.62 |
| Medicinal Plants and Neuroprotection | Lifetime | 251 | IN 62 | 94.88 |
| Advanced Glycation End Products research | Lifetime | 514 | IN 16 | 94.24 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 800 | IN 19 | 94.85 |
| Phytochemicals and Medicinal Plants | Lifetime | 237 | IN 137 | 93.20 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 8 | IN 1 | 99.04 |
| Alzheimer's disease research and treatments | 2021-2025 | 56 | IN 1 | 99.31 |
| Tryptophan and brain disorders | 2021-2025 | 63 | IN 1 | 98.04 |
| Medicinal Plants and Bioactive Compounds | 2021-2025 | 5 | IN 1 | 95.14 |
| Medicinal Plants and Neuroprotection | 2021-2025 | 19 | IN 4 | 97.34 |
| Mitochondrial Function and Pathology | 2021-2025 | 79 | IN 1 | 96.88 |
| Computational Drug Discovery Methods | 2021-2025 | 162 | IN 14 | 97.44 |
| Natural Antidiabetic Agents Studies | 2021-2025 | 68 | IN 10 | 96.59 |
| Phytochemistry and Biological Activities | 2021-2025 | 131 | IN 5 | 94.71 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 465 | IN 11 | 93.00 |
| Bioactive Compounds and Antitumor Agents | 2021-2025 | 85 | IN 15 | 90.03 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 287 | IN 8 | 89.24 |
| Natural product bioactivities and synthesis | 2021-2025 | 335 | IN 9 | 89.43 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 100 | IN 3 | 87.15 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 332 | IN 10 | 87.41 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 933 | IN 9 | 90.65 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 672 | IN 4 | 90.89 |
| Diverse Scientific Research Studies | 2021-2025 | 102 | IN 38 | 82.42 |
| Vitamin C and Antioxidants Research | 2021-2025 | 193 | IN 2 | 81.46 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 658 | IN 5 | 80.57 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 449 | IN 31 | 81.27 |
| Nerve injury and regeneration | 2021-2025 | 418 | IN 4 | 80.29 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 862 | IN 18 | 80.66 |
| Cellular transport and secretion | 2021-2025 | 588 | IN 9 | 76.94 |
| PARP inhibition in cancer therapy | 2021-2025 | 941 | IN 11 | 78.41 |
| FOXO transcription factor regulation | 2021-2025 | 68 | IN 2 | 72.61 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 635 | IN 26 | 74.51 |
| Curcumin's Biomedical Applications | 2021-2025 | 465 | IN 65 | 71.37 |
| Nuclear Receptors and Signaling | 2021-2025 | 329 | IN 12 | 68.72 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 431 | IN 10 | 70.30 |
| Phytochemical Studies and Bioactivities | 2021-2025 | 176 | IN 14 | 67.88 |
| Advanced Glycation End Products research | 2021-2025 | 616 | IN 31 | 66.33 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 916 | IN 19 | 65.24 |
| Berberine and alkaloids research | 2021-2025 | 381 | IN 33 | 57.11 |
| Natural Compound Pharmacology Studies | 2021-2025 | 419 | IN 22 | 47.33 |
